LONDON (Reuters) - Bristol-Myers Squibb has pulled ahead in the race to dominate the hot new cancer immunotherapy market but Merck & Co, Roche and AstraZeneca still have important opportunities to close the gap.
http://ift.tt/xePdMM
from Reuters: Health News
via animenewspro
Aucun commentaire:
Enregistrer un commentaire